Halozyme Therapeutics, Inc. (NasdaqGS:HALO) will look for M&A. Nicole LaBrosse, Chief Financial Officer said, “We have been consistent regarding our balanced capital allocation priorities. These include maintaining a strong balance sheet, capital return via share repurchases, and commitment to driving both internal and external growth via M&A. We have a strong balance sheet with cash, cash equivalents, and marketable securities as of the end of the fourth quarter of $740.9 million. We continue to expect our strong projected free cash flow, driven by our ENHANZE franchise, will support both our commitment to capital return as well as fund both internal and external growth via M&A”.